Copyright
©The Author(s) 2022.
World J Cardiol. Nov 26, 2022; 14(11): 599-616
Published online Nov 26, 2022. doi: 10.4330/wjc.v14.i11.599
Published online Nov 26, 2022. doi: 10.4330/wjc.v14.i11.599
Figure 8 Forest plot.
A: Highlighting impact of SGLT2-I on BW compared to placebo; B: SGLT2-I Type subgroup analysis performed for BW; C: SGLT2-I Dose subgroup analysis performed for BW. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor; BW: Body weight.
- Citation: Olagunju A, Yamani N, Kenny D, Mookadam M, Mookadam F, Unzek S. Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World J Cardiol 2022; 14(11): 599-616
- URL: https://www.wjgnet.com/1949-8462/full/v14/i11/599.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i11.599